Consistent with the idea that SCD patients show a higher risk of preclinical, AD-related neuroimaging and cognitive alterations, we were able to show that the cholinergic basal forebrain volume was smaller in SCD compared to controls matched for age, gender and ApoE status, consistent with previous findings in MCI and AD dementia. The gene discussed is APOE; the disease is Alzheimer disease.